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tality within 30 days of MRSA infection. Further prospective
studies are needed to examine the clinical signiﬁcance of an
upward ‘creep’ in vancomycin MIC values.346 14
CHEF- DRIII system. SCCmec typing and MLST were per-
ormed according to internationally standardized protocols.
Results: They were resistant to kanamycin (62%), fusidic
cid (42%), tetracycline (39.3%), erythromycin and clin-
amycin (21.5%), gentamicin (5.9%), streptomycin (6.7%),
rimethoprim (5.9%), mupirocin (6.6%) cadmium acetate
82.2%) and ethidium bromide (12.6%). All were suscepti-
le to vancomycin, teicoplanin and linezolid. One hundred
nd three (76.3%), 11 (8.14%), 9 (6.67%) and 12 (8.9%) iso-
ates carried SCCmec type IV, SCCmec —Iva, SCCmec-IVc and
CCmec - V genetic elements respectively. PFGE yielded 10
FGE types and subtypes with the majority of them belong-
ng to PFGE type 1 and subtypes (47.4%), type 2 (22.2%), type
(3.7%), type 4 (14.0%). Other PFGE types were present in
mall numbers MLST revealed 10 sequence types comprising
T80 (46.6%), ST30 (10.7%), ST5 (19.3%), ST6 (10.7%), ST8
3.6%), ST46 (3.6%), ST88 (3.6%), ST834 (3.6%) and ST950
3.6%). Isolates belonging to the same PFGE pattern had the
ame sequence type.
Conclusion: Although the isolates belonged to 10 differ-
nt sequence types, the ST80-SCCmec IV clone belonging to
FGE type 1 and subtypes was the most prevalent clone. Its
resence in all eight hospitals shows its continuing expansion
n Kuwait hospitals.
oi:10.1016/j.ijid.2010.02.388
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Background: Numerous community-associated MRSA (CA-
RSA) infections have been seen in healthy populations. To
etect CA-MRSA is important for clinicians because many
atal cases were reported. Staphylococcal cassette chromo-
ome mec (SCCmec) typing is useful for deﬁning CA-MRSA
lones. The rapid detection system for CA-MRSA is needed.
e established a convenient multiplex real-time PCR for
etection of SCCmec type assignment with detection of the
athogenicity analyzed MRSA clones in Nagasaki.
Methods: 776 MRSA isolated from different clinical speci-
ens, sputum, pus and blood at Nagasaki University Hospital
rom Jan. 2000 to Dec. 2007. All isolates were subjected to
IC testing and PCR for TSST-1(toxic shock syndrome toxin
), sec (enterotoxin type c), etb(exfoliative toxin type b),
nd PVL(Panton-Valentine Leucocidin). PCR was performed
sing a LightCycler 480 to amplify a total of 10 genes in the
ame run. The entire run time for this assay is approximately
hours. Based on these molecular typing methods, we char-
cterized the genetic background of MRSA strains isolated
n our hospital. The medical records were also reviewed for
he determination of nosocomial infection or the community
cquired infection.
Results: The 667 MRSA clones detected from pus were
lassiﬁed as SCCmec type II (77.7%), SCCmec type IV
dternational Congress on Infectious Diseases (ICID) Abstracts
19.2), and SCCmec type I (3.0). SCCmec type IV clones
as been increasing for 8years. 87.5% of SCCmec type II clone
ad TSST-1 and sec genes. 15 isolates were etb positive, all
f them isolated from pus. No isolate was PVL positive. Most
atients infected SCCmec type IV clone were classiﬁed as
osocomial infection.
Conclusion: Our system was thus the convenient and reli-
ble method for typing MRSA in Japan. SCCmec type II MRSA
hich possesses TSST-1 and sec genes was the major noso-
omial infection type in Japan. The present study indicated
he high rates of PVL negative SCCmec type IV in Nagasaki,
nd reveals for the drift of MRSA clones mixed the type of
osocomial infection and the type of community acquired
nfection.
oi:10.1016/j.ijid.2010.02.389
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Background: Methicillin-resistant Staphylococcus aureus
MRSA) has become a common cause of nosocomial and
ommunity-acquired infection. Vancomycin has become the
rug of choice given the emergence of MRSA; however, stud-
es have reported an increase in the vancomycin minimum
nhibitory concentration (MIC) and vancomycin treatment
ailure despite MICs within the susceptible range ()2g/mL).
imited studies have examined whether this increase in van-
omycin MIC is associated with patient outcome.
Methods: We reviewed the medical records of patients
iagnosed with MRSA bloodstream or lower extremity wound
nfection from January 1, 1998 through December 31, 2008.
ivariate and multivariate analyses were conducted to
xamine the association between vancomycin MIC and other
ovariates.
Results: 97 patients were diagnosed with a MRSA infec-
ion; 65% (63/97) of patients had a bloodstream infection
nd 35% (34/97) of patients had a wound infection. From
998 to 2003, MRSA with a low vancomycin MIC (≤1g/mL)
ere in themajority; however, from 2004 to 2008, MRSA with
high MIC (=2gg/mL) were in themajority. Therefore, over
ime, there was a signiﬁcant upward trend in vancomycin
IC values (p = 0.01). Logistic regression analysis revealed
hat a high vancomycin MIC was signiﬁcantly associated with
past medical history of malignancy (p = 0.04) and death
ithin 30 days of infection (p = 0.04) compared to a low
ancomycin MIC.
Conclusion: Our study has shown (1) vancomycin MIC val-
es have displayed an upward ‘creep’ over time, and (2)
igh MIC values of vancomycin is signiﬁcantly related to a
ast medical history of malignancy as well as higher mor-oi:10.1016/j.ijid.2010.02.390
